Brummer Multi Strategy AB Makes New Investment in Maravai LifeSciences Holdings, Inc. $MRVI

Brummer Multi Strategy AB bought a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the 4th quarter, Holdings Channel reports. The institutional investor bought 457,707 shares of the company’s stock, valued at approximately $1,488,000. Maravai LifeSciences accounts for about 9.0% of Brummer Multi Strategy AB’s holdings, making the stock its 6th largest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sprott Inc. bought a new stake in Maravai LifeSciences during the third quarter worth $29,000. Quantessence Capital LLC bought a new stake in Maravai LifeSciences during the third quarter worth $31,000. Abel Hall LLC bought a new stake in Maravai LifeSciences during the third quarter worth $33,000. CIBC Bancorp USA Inc. bought a new stake in Maravai LifeSciences during the third quarter worth $33,000. Finally, Ballentine Partners LLC bought a new stake in Maravai LifeSciences during the third quarter worth $37,000. 50.25% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wells Fargo & Company upped their target price on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a research note on Friday. Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $6.00 target price on shares of Maravai LifeSciences in a research note on Friday. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.70.

Maravai LifeSciences Price Performance

Shares of MRVI opened at $4.85 on Monday. Maravai LifeSciences Holdings, Inc. has a 52 week low of $1.95 and a 52 week high of $4.95. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -6.83 and a beta of 0.62. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.69 and a current ratio of 6.60. The stock has a fifty day moving average of $3.33 and a 200-day moving average of $3.39.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.29% and a negative net margin of 51.07%.The company had revenue of $65.84 million during the quarter, compared to analysts’ expectations of $53.00 million. As a group, sell-side analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.26 earnings per share for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.